AbCellera Biologics News

Piper Sandler Reaffirms Their Buy Rating on AbCellera Biologics (ABCL)

TipRanksFeb 23 07:33 ET

AbCellera Biologics Stock Upgraded to Buy on Q4 Results, R&D Progress

InvestingFeb 22 10:46 ET

AbCellera Biologics Analyst Ratings

BenzingaFeb 22 07:03 ET

AbCellera Biologics Analyst Ratings

BenzingaFeb 21 09:00 ET

Stifel Nicolaus Reaffirms Their Buy Rating on AbCellera Biologics (ABCL)

TipRanksFeb 21 08:14 ET

Analysts Offer Insights on Healthcare Companies: AbCellera Biologics (ABCL), Teladoc (TDOC) and Alnylam Pharma (ALNY)

TipRanksFeb 21 07:31 ET

Analysts Offer Insights on Healthcare Companies: Halozyme (HALO) and AbCellera Biologics (ABCL)

TipRanksFeb 20 21:30 ET

Buy Rating Affirmed for AbCellera Biologics Amid Positive TCE Program Prospects and Strategic Pipeline Focus

TipRanksJan 11 07:46 ET

Keybanc Initiates Coverage On AbCellera Biologics With Overweight Rating, Announces Price Target of $6

BenzingaDec 5, 2023 06:03 ET

AbCellera Biologics Analyst Ratings

BenzingaDec 5, 2023 06:01 ET

Leerink Partners Reaffirms Their Buy Rating on AbCellera Biologics (ABCL)

TipRanksDec 1, 2023 08:41 ET

TD Cowen Remains a Buy on AbCellera Biologics (ABCL)

TipRanksNov 2, 2023 21:05 ET

Piper Sandler Assumes AbCellera Biologics at Overweight, Announces Price Target of $20

BenzingaOct 13, 2023 06:29 ET

AbCellera Biologics Analyst Ratings

BenzingaOct 13, 2023 06:26 ET

Benchmark Maintains Buy on AbCellera Biologics, Lowers Price Target to $12

BenzingaAug 31, 2023 08:37 ET

AbCellera Biologics Analyst Ratings

BenzingaAug 31, 2023 08:35 ET

AbCellera Biologics Analyst Ratings

BenzingaAug 4, 2023 09:10 ET

Berenberg Bank Adjusts AbCellera Biologics Price Target to $34 From $38, Maintains Buy Rating

MT NewswiresAug 4, 2023 07:30 ET

Berenberg Bank Reaffirms Their Buy Rating on AbCellera Biologics (ABCL)

TipRanksAug 3, 2023 23:25 ET

AbCellera Biologics (ABCL) Gets a Buy From Berenberg Bank

TipRanksMay 24, 2023 19:35 ET